UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

                                 April 11, 2008

                                   ----------

                                 XENOMICS, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                     FLORIDA
                 (STATE OR OTHER JURISDICTION OF INCORPORATION)

             333-103083                                  04-3721895
      (COMMISSION FILE NUMBER)              (I.R.S. EMPLOYER IDENTIFICATION NO.)

                        420 Lexington Avenue. Suite 1701
                            New York, New York 10170
                    (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

                                 (212) 297-0808
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (SEE General Instruction A.2. below):

[ ]  Written communications  pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant  to Rule  13e-4(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))



ITEM      1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT.

     Subsequent to the approval of the disinterested members of the Board of
Directors, Xenomics, Inc. (the "Company") and Gian Luigi Longinotti-Buitoni, the
Executive Chairman of the Company ("Lead Investor") entered into Amendment No. 4
(the "Amendment"), dated as of April 11, 2008, to the Warrant and Put Option
Agreement originally dated as of November 30, 2006, as amended August 29, 2007,
October 30, 2007 and February 25, 2008 (the "Warrant and Put Option Agreement"),
pursuant to which the Amendment extended to May 15, 2008, the date on which the
Company may, at its sole discretion, exercise a put option (the "Put Option")
pursuant to which it may require the Lead Investor to invest in the Company up
to an additional $1,500,000 to purchase the Maximum Put Amount of Units at a
purchase price of $.55 per share of common stock, par value $0.0001 (the
"Shares"). Upon notification on or before May 15, 2008, the Lead Investor shall
purchase the number of Units specified in such notice by May 16, 2008 up to the
Maximum Put Amount. The Amendment is filed as Exhibit 4.1 to this report.
(Capitalized terms not otherwise defined herein are given the meaning ascribed
to them as set forth in the Amendment).

ITEM      9.01 FINANCIAL STATEMENTS AND EXHIBITS.

          (c)       Exhibits.

                    4.1       Form of Amendment No. 4 to Warrant and Put Option
                              Agreement dated April 11, 2008.



                                    SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           XENOMICS, INC.

Date: April 17, 2008                       By: /s/ Gian Luigi Longinotti-Buitoni
                                               ---------------------------------
                                           Gian Luigi Longinotti-Buitoni
                                           Executive Chairman



               AMENDMENT NO. 4 TO WARRANT AND PUT OPTION AGREEMENT

     This AMENDMENT NO. 4 (the "Fourth Amendment") to the WARRANT AND PUT OPTION
AGREEMENT (the "Agreement") originally dated as of November 30, 2006, by and
between Gian Luigi Longinotti-Buitoni (the "Lead Investor"), and Xenomics, Inc.
(the "Company"), as amended August 29, 2007, October 30, 2007, and February 25,
2008 is dated as of April 11, 2008.

WITNESSETH:

     WHEREAS, on November 30, 2006, the Lead Investor and the Company entered
into the Agreement and amended such Agreement on August 29, 2007, October 30,
2007; and February 25, 2008, and

     WHEREAS, the entire amount of the Financing Condition has not been met as
set forth in the Agreement; however, the Company and the Lead Investor wish to
amend the Agreement to extend the time in which the Company may exercise its
Maximum Put Amount;

     WHEREAS, the parties now desire to amend Section 3(b) of such Agreement in
order to preserve the Company's right to exercise the Maximum Put Amount until
May 15, 2008;

     NOW, THEREFORE, in consideration of and for the mutual promises and
covenants contained herein, and for other good and valuable consideration, the
receipt of which is hereby acknowledged, the Agreement is hereby amended as
follows:

1.   The last sentence of the definition of "Maximum Put Amount" in Section
     3(b)(i) is hereby replaced in its entirety with "In no event shall the
     Maximum Put Amount exceed $1,500,000 for the Units or $.55 per Share. The
     Lead Investor shall have the option to purchase an additional 2,727,272
     Shares (the "Additional Shares") at $.70 per Share or an additional
     $1,900,000 under the Warrants attached to aforesaid Units."

2.   Section 3(b)(ii) shall be replaced in its entirety with the following:
     "Since the Financing Condition has not been met, at the Company's sole
     discretion, upon written notice from the Company on or before May 15, 2008,
     by May 16, 2008 (the "Put Closing Date"), the Lead Investor shall purchase
     the number of Units specified in such notice up to the Maximum Put Amount
     divided by the applicable Exercise Price, i.e. $.55 per Share. On the Put
     Closing Date, the Lead Investor shall surrender this Warrant and the full
     Exercise Price of the Units specified in the Notice in immediately
     available funds against the Company's delivery of Lead Investor's
     Securities. If less than all of the Additional Shares which may then be
     acquired on the exercise of this Warrant are specified in the Notice, the
     Company shall cancel this Warrant and issue and deliver to the Lead
     Investor a new Warrant for the Lead Investor's Additional Shares
     remaining."

3.   The Company and the Lead Investor acknowledge that the Lead Investor's
     Warrants under Paragraph 1 of the Agreement shall be terminated other than
     the Lead Investor's option to purchase the Additional Shares underlying the
     Units referred to in Paragraphs 1 and 2 herein and other than the Warrants
     underlying the Maximum Put Option, which the Company may "put" to the Lead
     Investor pursuant to Paragraphs and 1 and 2 hereof.

4.   (A)  This Third Amendment shall be construed and interpreted in accordance
          with the laws of the State of New York without giving effect to the
          conflict of laws rules thereof or the actual domiciles of the parties.

     (B)  Except as amended hereby, the terms and provisions of the Agreement
          shall remain in full force and effect, and the Agreements and
          Amendments Nos. 1, 2 and 3 are in all respects ratified and confirmed.
          On and after the date of this Fourth Amendment, each reference in the
          Agreement to the "Agreement," "hereinafter," "herein," "hereunder,"
          "hereof," or words of like import shall mean and be a reference to the
          Agreement as amended by this Fourth Amendment. Capitalized terms not
          otherwise defined herein are given the meaning ascribed to them as set
          forth in the Agreement.

     (C)  This Fourth Amendment may be executed in one or more counterparts,
          each of which shall be deemed an original and all of which taken
          together shall constitute a single Amendment.

5.   Copies of all notices to the Company pursuant to Paragraph 14 of the
     Agreement shall also be sent to: Herrick, Feinstein LLP, 2 Park Avenue, New
     York, New York 10016, Attn: Ted D. Rosen, Esq.



IN WITNESS WHEREOF, the parties hereto have executed this Third Amendment as of
the date stated above.

                                         LEAD INVESTOR


                                         By:
                                         Gian Luigi Longinotti-Buitoni


                                         XENOMICS, INC.


                                         By:
                                         Name:     Gian Luigi Longinotti-Buitoni
                                         Title:    Executive Chairman